[HTML][HTML] Glycoprotein-D–adjuvant vaccine to prevent genital herpes
…, M Slaoui, M Denis, P Vandepapeliere… - … England Journal of …, 2002 - Mass Medical Soc
Background An effective prophylactic vaccine would help control the spread of genital
herpes. Methods We conducted two double-blind, randomized trials of a herpes simplex …
herpes. Methods We conducted two double-blind, randomized trials of a herpes simplex …
Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface …
P Vandepapelière, Y Horsmans, P Moris… - Vaccine, 2008 - Elsevier
A randomised, double-blind study assessing the potential of four adjuvants in combination
with recombinant hepatitis B surface antigen has been conducted to evaluate humoral and …
with recombinant hepatitis B surface antigen has been conducted to evaluate humoral and …
Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy: a randomized, controlled study of co-administration of HBsAg/AS02 …
P Vandepapeliere, GKK Lau, G Leroux-Roels… - Vaccine, 2007 - Elsevier
Induction of curative immune responses by therapeutic vaccination in chronic viral infections
such as chronic hepatitis B (CHB) is expected to be facilitated by reduction of viral load by …
such as chronic hepatitis B (CHB) is expected to be facilitated by reduction of viral load by …
Down‐regulation of interferon signature in systemic lupus erythematosus patients by active immunization with interferon α–kinoid
BR Lauwerys, E Hachulla, F Spertini… - Arthritis & …, 2013 - Wiley Online Library
Objective We developed interferon‐α–kinoid (IFN‐K), a drug composed of inactivated IFNα
coupled to a carrier protein, keyhole limpet hemocyanin. In human IFNα–transgenic mice …
coupled to a carrier protein, keyhole limpet hemocyanin. In human IFNα–transgenic mice …
A phase 1/2 clinical trial evaluating safety and immunogenicity of a varicella zoster glycoprotein e subunit vaccine candidate in young and older adults
I Leroux-Roels, G Leroux-Roels… - The Journal of …, 2012 - academic.oup.com
Background. An adjuvanted recombinant varicella zoster virus (VZV) subunit vaccine is
being developed for the prevention of herpes zoster and its complications. Methods. In a …
being developed for the prevention of herpes zoster and its complications. Methods. In a …
[PDF][PDF] Immunization with an adjuvant hepatitis B vaccine after liver transplantation for hepatitis B‐related disease
…, M Günther, R Neuhaus, P Vandepapeliere… - …, 2003 - Wiley Online Library
Patients who undergo transplantation for hepatitis B virus (HBV)‐related diseases are
treated indefinitely with hepatitis B hyperimmunoglobulin (HBIG) to prevent endogenous …
treated indefinitely with hepatitis B hyperimmunoglobulin (HBIG) to prevent endogenous …
Safety and immunogenicity of a hepatitis B vaccine formulated with a novel adjuvant system
…, I Desombere, A Safary, P Vandepapeliere… - Vaccine, 1998 - Elsevier
A formulation of recombinant hepatitis B surface antigen (HBsAg) combined with a novel
adjuvant system, SBAS4—a combination of aluminium salt and monophosphoryl lipid A …
adjuvant system, SBAS4—a combination of aluminium salt and monophosphoryl lipid A …
Randomized controlled trial of an adjuvanted human papillomavirus (HPV) type 6 L2E7 vaccine: infection of external anogenital warts with multiple HPV types and …
P Vandepapeliere, R Barrasso… - The Journal of …, 2005 - academic.oup.com
Background. Cellular immunity is involved in spontaneous clearance of anogenital warts
caused, most typically, by human papillomavirus (HPV) type 6 or 11, supporting the concept …
caused, most typically, by human papillomavirus (HPV) type 6 or 11, supporting the concept …
Interferon α kinoid induces neutralizing anti-interferon α antibodies that decrease the expression of interferon-induced and B cell activation associated transcripts …
J Ducreux, FA Houssiau, P Vandepapeliere… - …, 2016 - academic.oup.com
Abstract Objective. IFN α Kinoid (IFN-K) is a therapeutic vaccine composed of IFNα2b
coupled to a carrier protein. In a phase I/II placebo-controlled trial, we observed that IFN-K …
coupled to a carrier protein. In a phase I/II placebo-controlled trial, we observed that IFN-K …
Strong and persistent CD4+ T-cell response in healthy adults immunized with a candidate HIV-1 vaccine containing gp120, Nef and Tat antigens formulated in three …
I Leroux-Roels, M Koutsoukos, F Clement, S Steyaert… - Vaccine, 2010 - Elsevier
This randomized double-blind study aimed to determine the safety and immunogenicity of a
gp120/NefTat candidate human immunodeficiency virus type 1 (HIV-1) vaccine formulated …
gp120/NefTat candidate human immunodeficiency virus type 1 (HIV-1) vaccine formulated …